Swiss National Bank Sells 20,100 Shares of DaVita Inc. (NYSE:DVA)

Swiss National Bank decreased its holdings in DaVita Inc. (NYSE:DVAFree Report) by 10.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 175,100 shares of the company’s stock after selling 20,100 shares during the period. Swiss National Bank’s holdings in DaVita were worth $16,552,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. raised its stake in DaVita by 5.4% in the first quarter. BlackRock Inc. now owns 5,083,162 shares of the company’s stock worth $412,295,000 after buying an additional 260,783 shares in the last quarter. State Street Corp raised its stake in DaVita by 2.5% in the second quarter. State Street Corp now owns 2,606,222 shares of the company’s stock worth $261,847,000 after buying an additional 63,136 shares in the last quarter. Norges Bank acquired a new position in shares of DaVita during the fourth quarter worth $116,373,000. Morgan Stanley increased its position in shares of DaVita by 37.9% during the fourth quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock worth $92,042,000 after purchasing an additional 339,051 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of DaVita by 3.2% during the second quarter. Geode Capital Management LLC now owns 1,203,850 shares of the company’s stock worth $120,645,000 after purchasing an additional 37,261 shares in the last quarter. Institutional investors own 84.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DVA shares. UBS Group reduced their price target on DaVita from $142.00 to $113.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. TheStreet raised DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, DaVita has an average rating of “Moderate Buy” and a consensus target price of $102.67.

View Our Latest Analysis on DVA

DaVita Price Performance

Shares of DVA opened at $109.86 on Friday. The firm has a market capitalization of $10.03 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 0.75 and a beta of 1.00. The company has a debt-to-equity ratio of 6.01, a current ratio of 1.24 and a quick ratio of 1.19. DaVita Inc. has a 1-year low of $71.51 and a 1-year high of $116.97. The company’s fifty day moving average price is $106.98 and its 200-day moving average price is $98.84.

DaVita Company Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Read More

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVAFree Report).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.